Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Income from Continuing Operations: 2018-2022

Historic Income from Continuing Operations for ADC Therapeutics (ADCT) over the last 5 years, with Dec 2022 value amounting to -$153,522.

  • ADC Therapeutics' Income from Continuing Operations rose 12.93% to -$45.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$153.5 million, marking a year-over-year decrease of 11.71%. This contributed to the annual value of -$153,522 for FY2022, which is 43.76% up from last year.
  • ADC Therapeutics' Income from Continuing Operations amounted to -$153,522 in FY2022, which was up 43.76% from -$272,984 recorded in FY2021.
  • ADC Therapeutics' Income from Continuing Operations' 5-year high stood at -$115,320 during FY2019, with a 5-year trough of -$272,984 in FY2021.
  • Over the past 3 years, ADC Therapeutics' median Income from Continuing Operations value was -$245,636 (recorded in 2020), while the average stood at -$224,047.
  • Per our database at Business Quant, ADC Therapeutics' Income from Continuing Operations slumped by 113.00% in 2020 and then soared by 43.76% in 2022.
  • ADC Therapeutics' Income from Continuing Operations (Yearly) stood at -$122,648 in 2018, then increased by 5.97% to -$115,320 in 2019, then slumped by 113.00% to -$245,636 in 2020, then decreased by 11.13% to -$272,984 in 2021, then soared by 43.76% to -$153,522 in 2022.